Radium-223 dichloride was recently approved for the treatment of men with symptomatic castration-resistant prostate cancer without visceral disease. An understanding of when to use this first-in-class α-emitting agent in the context of the other new treatments is evolving.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Henriksen, G., Breistøl, K., Bruland, Ø. S., Fodstad, Ø. & Larsen, R. H. Significant antitumor effect from bone-seeking, α-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 62, 3120–3125 (2002).
Henriksen, G., Fisher, D. R., Roeske, J. C., Bruland, Ø. S. & Larsen, R. H. Targeting of osseous sites with α-emitting 223Ra: comparison with the β-emitter 89Sr in mice. J. Nucl. Med. 44, 252–259 (2003).
Nilsson, S. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 8, 587–594 (2007).
Nilsson, S. et al . Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin. Genitourin. Cancer 11, 20–26 (2013).
Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).
de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).
Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
Acknowledgements
The author thanks the Department of Defense Prostate Cancer Research Program (USA) for partial support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has acted as a consultant and received research support from the following company: Bayer; and has received research funding and act as a consultant for the following companies: Cougar Biotech, Dendreon, Johnson & Johnson, Janssen, Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Higano, C. α-Emitting radium-223—additional choices, more unknowns. Nat Rev Clin Oncol 10, 612–613 (2013). https://doi.org/10.1038/nrclinonc.2013.168
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.168
